Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 26, 2026
Reporting period
Not applicable
Filed with the SEC
Mar 3, 2026
OfficerGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001989533-26-000006
Filed / recorded
Mar 3, 2026, 3:04 AM UTC
Added to OQRO
Oct 6, 2026, 7:59 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Jazz Pharmaceuticals plc
Issuer CIK
1232524
Ticker
JAZZ
Reporting person
Mary Elizabeth Henderson
Relationship
Officer
Officer title
SVP, Technical Operations
Security
Ordinary Shares
Table
Non-derivative (Table I)
Transaction date
Feb 26, 2026
Transaction code
A
Shares / units
4,447
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
34,071
Ownership form
Direct
Amendment
No
Footnotes from the filing
These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.